Department of Biotechnology, Middle East Technical University, Ankara, Turkey.
Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
Curr Drug Targets. 2018 Feb 8;19(3):202-212. doi: 10.2174/1389450117666160401124624.
Smart nanocarriers have been designed for tissue-specific targeted drug delivery, sustained or triggered drug release and co-delivery of synergistic drug combinations to develop safer and more efficient therapeutics.
Advances in drug delivery systems provide reduced side effects, longer circulation half-life and improved pharmacokinetics.
Smart drug delivery systems have been achieved successfully in the case of cancer. These nanocarriers can serve as an intelligent system by considering the differences of tumor microenvironment from healthy tissue, such as low pH, low oxygen level, or high enzymatic activity of matrix metalloproteinases.
The performance of anti-cancer agents used in cancer diagnosis and therapy is improved by enhanced cellular internalization of smart nanocarriers and controlled drug release. Here, we review targeting, cellular internalization; controlled drug release and toxicity of smart drug delivery systems. We are also emphasizing the stimulus responsive controlled drug release from smart nanocarriers.
智能纳米载体已被设计用于组织特异性靶向药物递送、持续或触发药物释放以及协同药物组合的共递送来开发更安全、更有效的治疗方法。
药物递送系统的进步提供了减少副作用、延长循环半衰期和改善药代动力学的效果。
在癌症的情况下，智能药物递送系统已经取得了成功。这些纳米载体可以通过考虑肿瘤微环境与健康组织的差异，例如低 pH 值、低氧水平或基质金属蛋白酶的高酶活性，作为智能系统。
通过增强智能纳米载体的细胞内化和控制药物释放，提高了用于癌症诊断和治疗的抗癌剂的性能。在这里，我们综述了靶向性、细胞内化、控制药物释放和智能药物递送系统的毒性。我们还强调了智能纳米载体的刺激响应控制药物释放。
